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kinci et al. (1) report that lower 24-h
urinary sodium excretion is paradox-
icallyassociatedwithanincreasedrisk
of all-cause and cardiovascular mortality
in type 2 diabetes. They conclude, “Such
data call into question universal recom-
mendations that all adults should en-
deavor to reduce their salt intake.” The
authors are to be commended for basing
theirprospectiveobservationalstudyonre-
peated24-hurineexcretions.However,we
believe that their conclusions need to be
treated with caution for several reasons.
First, as the authors also state, this is
an observational study, prone to unmea-
sured and residual confounding that may
have played a dominant role in eliciting
these paradoxical results.
Second,andpossiblyaconsequenceof
the ﬁrst, the studied population may not
be a representative population. In partic-
ular, Ekinci et al. showed that a lower
systolic blood pressure was also associated
with a signiﬁcantly increased risk of all-
cause and cardiovascular mortality. Does
this mean that we should question the
value of blood pressure lowering as well?
Moreover, subjects with a lower 24-h uri-
nary sodium excretion were older, more
often female, and less often obese. It is
therefore likely that these subjects were
smaller, had lower energy requirements,
andaccordinglyloweroverallfoodintake
and proportionally lower sodium intake.
It would be important therefore, to verify
whether adjustment for body surface
area or 24-h creatinine excretion, as a
proxy for physical ﬁtness, would affect
the results.
Third, a lack of a full range of sodium
intake (in particular to the low end) may
have hampered a correct conclusion. The
lower tertilehad,150mmolNa/daycut-
off, where the authors do not report the
average of this group. This may still have
been higher than the recommended in-
take of 5–6 g of salt daily. This would
render it difﬁcult to accept excess activa-
tion of the renin-angiotensin-aldosterone
system (RAAS) or sympathetic nervous
system as a mechanism for the increased
mortality rates, as these neurohormonal
pathways are typically activated when salt
consumption is below 3 g/day (sodium ex-
cretion;50mmol/day).Indeedinarecent
study in subjects with type 1 diabetes,
both a very low (,50 mmol/day) and
high urinary sodium excretion (.200
mmol/day)wereassociatedwithincreased
mortality, while subjects with the guide-
line recommended salt intake of 5–6g
were at lowest risk (2). These contrasting
results are physiologically difﬁcult to ex-
plainandillustrateagainthecomplexityof
the observational studies.
No interaction was detected with the
modality of antihypertensive therapy.
This is surprising as moderate salt re-
striction consistently potentiates the ef-
fect of RAAS blockade on blood pressure,
albuminuria, and hard renal end points
(3). In patients with renal disease, salt re-
striction even overcomes resistance to
RAAS blockade, likely by additional inhi-
bition of tissue angiotensin-converting
enzyme (4).
Although observational studies can
be useful to generate interesting hypoth-
eses, they never provide the true answer.
As the authors mention themselves, ran-
domized controlled trials are necessary to
truly assess the impact of salt reduction
on mortality. We submit that the cur-
rently available data suggest that such
trialsmaydemonstratethatdietarysaltre-
duction reduces the risk of mortality (5).
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